Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 5/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148663 | 0.83 | LPL (0.44) | ALDH1A1CA1CA2CA9LPL | |
| SCHEMBL30544472 | 0.83 | LPL (0.44) | ALDH1A1CA1CA2CA9LPL | |
| SCHEMBL31217258 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MAPK1CA1CA2CA9 | |
| SCHEMBL5243207 | 0.81 | CA1 (0.61) | CA1CA2CA9LPLLIPG | |
| SCHEMBL6165864 | 0.78 | ALDH1A1 (0.78) | ALDH1A1MAPK1MMP13NPC1RAB9A | |
| SCHEMBL25981483 | 0.77 | LPL (0.40) | ALDH1A1MAPK1CA1CA2CA9 | |
| SCHEMBL257873 | 0.75 | ALDH1A1 (0.69) | ALDH1A1MAPK1MMP13NPC1RAB9A | |
| SCHEMBL623833 | 0.75 | CA1 (0.54) | ALDH1A1CA1CA2CA9LPL | |
| SCHEMBL25658494 | 0.75 | CA1 (0.54) | CA1CA2CA9LPLLIPG | |
| SCHEMBL5899727 | 0.75 | LPL (0.65) | CA1CA2CA9LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-10059675-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-2964639-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9163008-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163008-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163008-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| WO-2014135955-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135955-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2013030665-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030665-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | ALDH1A1 1063/4885MAPK1 3702/4885CA1 1637/4885 |
| US-10059675-B2 | Pyrimidines as sodium channel blockers | P2RX3, CACNA1A, P2RX4 | ALDH1A1 668/4885MAPK1 3105/4885CA1 3183/4885 |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | ALDH1A1 668/4885MAPK1 3105/4885CA1 3183/4885 |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | P2RX3, CACNA1A, P2RX4 | ALDH1A1 668/4885MAPK1 3105/4885CA1 3183/4885 |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX1, P2RX4, P2RX2 | ALDH1A1 531/4885MAPK1 3251/4885CA1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.